XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | 0.66 | 0.96 | +45.45% | $317.0M | ✅ Beat | +1.55% | +7.67% | -2.07% |
| 2026-02-26 | Q4 2025 | 0.66 | 0.82 | +24.24% | $358.0M | ✅ Beat | +1.04% | -4.92% | -14.06% |
| 2025-10-30 |
| Q3 2025 |
| 0.40 |
| 0.72 |
| +80.00% |
| $314.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | 0.26 | 0.51 | +96.15% | $302.0M | ✅ Beat | +3.45% | +9.16% | +20.20% |
| 2025-04-24 | Q1 2025 | 0.23 | 0.41 | — | $266.0M | ✅ Beat | +7.43% | +7.34% | +9.90% |
| 2025-02-20 | Q4 2024 | 0.26 | 0.32 | +23.08% | $298.0M | ✅ Beat | -6.01% | -1.22% | +12.35% |
| 2024-10-24 | Q3 2024 | 0.36 | 0.54 | +50.00% | $307.0M | ✅ Beat | +2.62% | +2.74% | +24.17% |
| 2024-07-25 | Q2 2024 | 0.14 | 0.44 | +214.29% | $299.0M | ✅ Beat | -2.29% | +4.05% | -4.89% |
Showing last 8 quarters.